CN1596105A - 含有甾类激素和含有丙二醇单辛酸酯的透皮治疗系统 - Google Patents

含有甾类激素和含有丙二醇单辛酸酯的透皮治疗系统 Download PDF

Info

Publication number
CN1596105A
CN1596105A CNA028239059A CN02823905A CN1596105A CN 1596105 A CN1596105 A CN 1596105A CN A028239059 A CNA028239059 A CN A028239059A CN 02823905 A CN02823905 A CN 02823905A CN 1596105 A CN1596105 A CN 1596105A
Authority
CN
China
Prior art keywords
transdermal therapeutic
therapeutic system
active component
multinomial
estradiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028239059A
Other languages
English (en)
Inventor
F·特奥巴尔德
R·艾夫勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Publication of CN1596105A publication Critical patent/CN1596105A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

本发明涉及含有至少一种甾类激素和作为渗透促进剂的丙二醇单辛酸酯的透皮治疗系统。本发明也涉及所述治疗系统的制备方法，以及其在激素替代治疗和避孕中的使用。

Description

含有甾类激素和含有丙二醇单辛 酸酯的透皮治疗系统
透皮治疗系统(TTS)是一种药物制剂形式，其具有层状结构，有一个不渗透活性成分的背衬层、一个含有活性成分的储库层及可以保证牢固接触使用者皮肤表面的粘贴层。有整体基质系统的类型，其中含有活性成分的储库层和粘贴层是同一的；有储库的类型，其中附加的速度-控制膜被置于含有活性成分的储库层与粘贴层之间；有具有至少两个含有活性成分的储库层的多层基质系统的类型，以及含有微储库的TTS类型。共同的是，在整个给药期间它们能持续地提供活性成分。因此在它们的浓度时间关系上同样是持续滴注。现今在医药市场上有许多具有不同活性成分的透皮治疗系统。
对于透皮治疗系统，最重要的适应征领域之一是激素替代治疗。特别是绝经后的激素替代可以有利地通过透皮治疗系统实现。在初期主要使用含有雌激素的单一制剂于绝经后的激素替代，随后的趋势是使用含有雌激素和促孕激素的透皮组合贴剂的组合。这样的用于避孕的活性成分的组合的应用同样可以借助透皮治疗系统。
睾酮，这种雄性激素同样也在甾类激素中应用于激素替代治疗(例如，用于治疗性腺功能减退)。
为了达到对于上述适应征所需要的血浆浓度，经常需要所谓的渗透促进剂(渗透增强剂)。它们增强活性成分从透皮治疗系统到血循环的转移。另外，它们增强透皮治疗系统活性成分的利用，同样也是药学-经济的原因所要求和值得做的。这意味着同样的治疗效果是可能以负载在透皮治疗系统中较少的活性成分达到。对于患者使用这种渗透促进剂的优点是，透皮治疗系统应用的面积减少，由此可以增加使用者的顺应性。
US 5,122,383公开了脱水山梨糖醇酯的使用，US 4,863,738公开了甘油单油酸酯的使用，已知分别在透皮治疗系统甾类的应用中作为渗透促进剂。
EP-A-279 977描述了丙二醇月桂酸酯和丙二醇二壬酸酯作为渗透促进剂用于性激素(孕酮和雌二醇)的透皮给药。
EP-A-272 987公开了丙二醇的单和双脂肪酸酯的使用，特别是丙二醇单和双月桂酸酯、丙二醇单棕榈酸酯、丙二醇单硬脂酸酯和丙二醇单油酸酯在透皮治疗系统中作为经皮的吸收增强剂，其中活性成分还可以有甾类和芬太尼或芬太尼衍生物。
现在令人惊奇地发现，在丙二醇单脂肪酸酯的使用中，在现有技术中作为渗透促进剂使用的众多丙二醇脂肪酸酯中未提及的，即丙二醇单辛酸酯在含有甾类激素的透皮系统中作为渗透促进剂的使用得到了意料不到的高的活性成分转运流，特别是促孕激素类和睾酮。根据本发明考虑下列用作为甾类激素：雌二醇、乙炔雌二醇，作为促孕激素类的孕酮、甲羟基孕酮、羟基孕酮、左炔诺孕酮、醋酸炔诺酮、炔诺孕酮、利奈孕酮、双醋炔诺醇、烯丙雌醇、孕激素(17α)-17-羟基-11-亚甲基-19-去甲孕甾-4，15-二烯-20-炔-3-酮(Org 30659的命名，由Organon，Oss，NL提供)以及其它，如雄性激素睾酮(在此并非受限于所列举的)。
以下实施例1和2显示，使用5％丙二醇单辛酸酯可以提高活性成分的转运约15％(促孕激素类)或约20％(睾酮)。
测量按以下执行：使用一种经修饰的Franz扩散细胞和分别使用4.1cm2有效扩散面积的透皮治疗系统。测试温度是32℃。在人类皮肤的表皮测量活性成分的转运流。使用的受体是0.1％羟丙基-β-环糊精+0.1％NaN3的水溶液，受体的体积是9ml(32、48、56和72小时后体积变化)。
实施例1
配方     重量％     3天后经累积的活性成分量[μg/cm2]
促孕激素(0rg 30659)Durotak 2287     5.095.0     44.7
促孕激素(Org 30659)Durotak 2287丙二醇单辛酸酯     5.090.05.0     51.3
实施例2
配方     重量％     3天后经累积的活性成分量[μg/cm2]
睾酮(Org 30659)Durotak 2287     2.098.0     30.2
睾酮(Org 30659)Durotak 2287丙二醇单辛酸酯     2.093.05.0     36.2

Claims (10)

1.透皮治疗系统，其含有至少一种甾类激素和作为渗透促进剂的丙二醇单辛酸酯。
2.根据权利要求1的透皮治疗系统，其特征在于，作为甾类激素使用雌二醇、乙炔雌二醇、孕酮、甲羟基孕酮、羟基孕酮、左炔诺孕酮、(17α)-17-羟基-11-亚甲基-19-去甲孕甾-4，15-二烯-20-炔-3-酮(Org30659)、醋酸炔诺酮、炔诺孕酮(Norgestrel)、利奈孕酮、烯丙雌醇、双醋炔诺醇或睾酮。
3.根据权利要求1或2的透皮治疗系统，其特征在于，含有促孕激素与活性成分雌二醇或乙炔基雌二醇的组合。
4.根据权利要求3的透皮治疗系统，其特征在于，作为促孕激素含有以Org30659命名的化合物。
5.根据前述权利要求一项或多项的透皮治疗系统，其特征在于，含有活性成分的基质由一种聚合物选自聚丙烯酸酯、聚二甲基硅氧烷、聚异丁烯、聚苯乙烯、苯乙烯-异戊二烯-苯乙烯嵌段共聚物、苯乙烯-丁二烯-苯乙烯嵌段共聚物、树脂、乙基乙烯乙酸酯或至少两种上述聚合物的组合物组成。
6.根据前述权利要求一项或多项的透皮治疗系统，其特征在于，丙二醇单辛酸酯的含量为1-20重量％，优选为2-10重量％。
7.根据前述权利要求一项或多项的透皮治疗系统，其特征在于，用于激素替代治疗。
8.根据权利要求1-6中一项或多项的透皮治疗系统，其特征在于，用于避孕。
9.丙二醇单辛酸酯用于提高甾类激素的透皮活性成分转运的用途。
10.根据权利要求9的用途，其特征在于，相关的甾类激素选自雌二醇、乙炔雌二醇、孕酮、甲羟孕酮、羟基孕酮、左炔诺孕酮、(17α)-17-羟基-11-亚甲基-19-去甲孕甾-4，15-二烯-20-炔-3-酮(Org30659)、醋酸炔诺酮、炔诺孕酮、利奈孕酮、烯丙雌醇、双醋炔诺醇或睾酮。
CNA028239059A 2001-12-01 2002-11-16 含有甾类激素和含有丙二醇单辛酸酯的透皮治疗系统 Pending CN1596105A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10159120A DE10159120B4 (de) 2001-12-01 2001-12-01 Steroidhormonhaltige transdermale therapeutische Systeme enthaltend Propylenglycolmonocaprylat und seine Verwendung
DE10159120.9 2001-12-01

Publications (1)

Publication Number Publication Date
CN1596105A true CN1596105A (zh) 2005-03-16

Family

ID=7707752

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028239059A Pending CN1596105A (zh) 2001-12-01 2002-11-16 含有甾类激素和含有丙二醇单辛酸酯的透皮治疗系统

Country Status (17)

Country Link
US (1) US20050118244A1 (zh)
EP (1) EP1448175A1 (zh)
JP (1) JP2005531493A (zh)
KR (1) KR100908970B1 (zh)
CN (1) CN1596105A (zh)
AU (1) AU2002365624B2 (zh)
BR (1) BR0214634A (zh)
CA (1) CA2465395A1 (zh)
DE (1) DE10159120B4 (zh)
HU (1) HUP0402213A2 (zh)
IL (1) IL162196A0 (zh)
MX (1) MXPA04005211A (zh)
NZ (1) NZ533159A (zh)
PL (1) PL368734A1 (zh)
RU (1) RU2317813C2 (zh)
WO (1) WO2003047555A1 (zh)
ZA (1) ZA200403658B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111542311A (zh) * 2017-12-27 2020-08-14 东亚St株式会社 用于治疗痴呆症的含有多奈哌齐的透皮吸收制剂

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3474283A1 (en) 2007-05-30 2019-04-24 Ascensia Diabetes Care Holdings AG Method and system for managing health data
FR2924942B1 (fr) * 2007-12-14 2012-06-15 Pf Medicament Compositions pharmaceutiques transcutanees contenant une hormone steroidienne
JP2011121866A (ja) * 2008-03-31 2011-06-23 Rohto Pharmaceutical Co Ltd 皮膚外用組成物
RU2648827C2 (ru) 2010-03-28 2018-03-28 Эвестра, Инк. Внутривлагалищное устройство для доставки лекарственного средства
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
RU2018133932A (ru) 2016-04-01 2020-05-12 Терапьютиксмд, Инк. Фармацевтическая композиция стероидного гормона
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006342A (en) * 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
US4863738A (en) * 1987-11-23 1989-09-05 Alza Corporation Skin permeation enhancer compositions using glycerol monooleate
US5019395A (en) * 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
US4942158A (en) * 1988-10-13 1990-07-17 Eastman Kodak Transdermal steroid penetrant compositions and methods utilizing isopropanol and isobutanol
JPH02233621A (ja) * 1989-03-07 1990-09-17 Nikken Chem Co Ltd 経皮吸収促進剤及びこれを含有する医薬外用製剤
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
PT99338A (pt) * 1990-10-29 1992-10-30 Alza Corp Processo para a preparacao de composicoes de farmacos anticoncepcionais administradas transdermicamente contendo uma mistura dum estrogeno e gestodeno e dispositivos para a sua administracao transdermica
US5122383A (en) * 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
JP2960832B2 (ja) * 1992-05-08 1999-10-12 ペルマテック テクノロジー アクチェンゲゼルシャフト エストラジオールの投与システム
GB2273044B (en) * 1992-12-02 1997-04-09 Pacific Chem Co Ltd Medicinal patches for percutaneous administration
DE4329242A1 (de) * 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
EP0782449B1 (en) * 1994-09-22 2003-04-09 Akzo Nobel N.V. Process of making dosage units by wet granulation
CA2159419C (en) * 1994-10-17 2006-07-04 Pieter De Haan Solid pharmaceutical composition comprising an excipient capable of binding water
EP0897927A1 (en) * 1997-08-11 1999-02-24 Akzo Nobel N.V. Novel crystalline form of the progestagen - (17alpha) 17-hydroxy-11-methylene-19-nor-pregna-4,15-dien-2 0-yn-3-one(Org 30659)
IT1294748B1 (it) * 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
ATE487491T1 (de) * 1999-02-19 2010-11-15 Takeda Pharmaceutical Präparationen zur perkutanen aufnahme von zusammnesetzungen die einen angiotensin-ii- rezeptorantagonismus aufweisen
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
MXPA02005224A (es) * 1999-11-24 2003-09-25 Agile Therapeutics Inc Sistema y procedimiento mejorado para la administracion transdermica de un anticonceptivo.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111542311A (zh) * 2017-12-27 2020-08-14 东亚St株式会社 用于治疗痴呆症的含有多奈哌齐的透皮吸收制剂
CN111542311B (zh) * 2017-12-27 2023-07-14 东亚St株式会社 用于治疗痴呆症的含有多奈哌齐的透皮吸收制剂

Also Published As

Publication number Publication date
KR100908970B1 (ko) 2009-07-22
DE10159120B4 (de) 2006-08-17
BR0214634A (pt) 2004-11-03
PL368734A1 (en) 2005-04-04
JP2005531493A (ja) 2005-10-20
RU2317813C2 (ru) 2008-02-27
EP1448175A1 (de) 2004-08-25
AU2002365624B2 (en) 2007-11-22
NZ533159A (en) 2005-12-23
US20050118244A1 (en) 2005-06-02
KR20050044628A (ko) 2005-05-12
IL162196A0 (en) 2005-11-20
AU2002365624A1 (en) 2003-06-17
MXPA04005211A (es) 2004-08-19
DE10159120A1 (de) 2003-06-12
CA2465395A1 (en) 2003-06-12
WO2003047555A1 (de) 2003-06-12
ZA200403658B (en) 2004-09-01
RU2004120067A (ru) 2005-04-10
HUP0402213A2 (hu) 2005-02-28

Similar Documents

Publication Publication Date Title
CN1596105A (zh) 含有甾类激素和含有丙二醇单辛酸酯的透皮治疗系统
JP6072725B2 (ja) イン・サイチュシールを有する経皮送達デバイス
JP2974969B2 (ja) 経皮ドラッグデリバリーのための固体マトリックスシステム
EP3179989B1 (en) Silicone-containing acrylic polymers for transdermal drug delivery compositions
EP0876131B1 (en) Drug delivery compositions for improved stability of androgens
US5252334A (en) Solid matrix system for transdermal drug delivery
IE69752B1 (en) Transdermal estrogen/progestin dosage unit system and process
JPH08165251A (ja) 溶解剤および該溶解剤を含有する外用製剤
JPH10512245A (ja) 酸に不安定な薬物の経皮送達のための組成物および方法
JPH11222443A (ja) 経皮吸収促進組成物および経皮吸収製剤
CN101102754A (zh) 包含孕酮a特异性配体（prasl）作为活性成分的透皮贴片
KR20190039692A (ko) 메틸페니데이트 또는 이의 염을 함유하는 경피 전달 시스템 및 이의 방법
JPH09268123A (ja) 局所麻酔用貼付剤
CA2336654C (en) Plaster which contains steroids, and a method for the production and use thereof
KR20090101579A (ko) 펜타닐을 함유한 경피 흡수제
CA2494915C (en) Female hormone-containing patch
JP3461401B2 (ja) 経皮投与用テープ剤
JP2001058961A (ja) 経皮吸収促進剤及び経皮吸収型製剤
JPH01297069A (ja) 粘着剤組成物
CN108606963B (zh) 含有屈螺酮和雌激素的复方避孕贴、制备方法及应用
JPS61221121A (ja) テ−プ製剤
JPS6212725A (ja) 外用医薬製剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication